AAS - Meklēšanas rezultāti

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

daxas

astrazeneca ab - roflumilast - plaušu slimība, hroniska obstruktīva - zāles obstruktīvu elpceļu slimību, - daxas ir indicēts uzturošā terapija smaga hroniska obstruktīva plaušu slimība (hops) (fev1 post-bronchodilator mazāk nekā 50 % prognozēja) saistīta ar hronisku bronhītu pieaugušiem pacientiem ar biežiem exacerbations vēsturi kā papildinājumu, lai bronchodilator ārstēšana.

Eiropas Savienība - latviešu - EMA (European Medicines Agency)

nucala

glaxosmithkline trading services - mepolizumabs - astma - zāles obstruktīvu elpceļu slimību, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.